NL-OMON37977已完成3 期
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer - Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients with NSCLC-C - Helsinn HT-ANAM-301 study (ROMANA 1)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 2
研究概览
简要总结
Trial is onging in other countries
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Females and males at least 18 years of age
- •Documented histologic or cytologic diagnosis of AJCC Stage III or IV NSCLC. Stage III patients must have unresectable disease.
- •With regard to chemotherapy and/or radiation therapy:
- •o Patients may be receiving maintenance chemotherapy.
- •o Patients planning to initiate a new chemotherapy and/or radiation therapy
- •regimen may do so only within ±14 days of randomization.
- •o Patients may have completed a chemotherapy and/or radiation therapy
- •and/or have no plan to initiate a new regimen within 12 weeks from
- •randomization. At least 14 days must elapse from the completion of the
- •chemotherapy and/or radiation therapy prior to randomization.
- •Involuntary weight loss of *5% body weight within 6 months prior to screening or a screening BMI <20 kg/m2. Weights may have been measured or obtained and documented by patient history.
- •Body mass index *30 kg/m2
- •ECOG performance status *2 (Appendix I)
- •Estimated life expectancy of >4 months at the time of screening
- •Adequate hepatic function, defined as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels *5 * upper limit of normal (ULN)
- •Adequate renal function, defined as creatinine *2 * ULN, or calculated creatinine clearance *30 ml/minute
- •The patient is able to understand and comply with the procedures for the Hand Grip Strenght evaluation
- •If the patient is a woman of childbearing potential or a fertile man, he/she must agree to use an effective form of contraception during the study and for 30 days following the last dose of study medication (an effective form of contraception is abstinence, a hormonal contraceptive, or a double-barrier method)
- •Must be willing and able to give signed informed consent and, in the opinion of the Investigator, to comply with the protocol tests and procedures.
排除标准
- •Other forms of lung cancer (eg, small cell, mesothelioma)
- •Women who are pregnant or breast-feeding
- •Known HIV, hepatitis (B & C), or active tuberculosis
- •Patients who are currently actively receiving chemotherapy and/or radiation therapy for disease treatment. Patients must not be planning to initiate chemotherapy and/or radiation therapy in the middle of the 12-week treatment period at the time of randomization.
- •Had major surgery within 4 weeks prior to randomization. Patients must be well recovered from acute effects of surgery prior to screening. Patients should not have plans to undergo major surgical procedures during the treatment period.
- •Currently taking prescription medications intended to increase appetite or treat weight loss;
- •Patients unable to readily swallow oral tablets. Patients with severe gastrointestinal disease or intractable or frequent vomiting are excluded
- •Has an active, uncontrolled infection
- •Has uncontrolled diabetes mellitus
- •Has untreated clinically relevant hypothyroidism
- •Has known or symptomatic brain metastases
- •Patients receiving strong CYP3A4 inhibitors within 14 days of randomization
- •Patients receiving tube feedings or parenteral nutrition (either total or partial). Patients must have discontinued these treatments for at least 6 weeks prior to Day 1, and throughout the study duration
- •Other clinical diagnosis, ongoing or intercurrent illness that in the Investigator*s opinion would prevent the patient*s participation
- •Has had previous exposure to Anamorelin HCl
- •Patients actively receiving a concurrent investigational agent
研究者
相似试验
已完成
3 期
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer - Cachexia (NSCLC-C): An Extension Study;(ROMANA-3)cachexiewasting syndroom1000301810027656NL-OMON38190Helsinn Therapeutics (U.S.), Inc1
已完成
4 期
Individualized dosing of AMinoglycosides, quInolones and Glycopeptide antibiotics in (morbidly) Obese patients (AMIGO)(Morbid) obesityoverweight10004018NL-OMON46981Sint Antonius Ziekenhuis117
已完成
不适用
MEDIASTINAL STAGING OF NON SMALL CELL LUNG CANCER BY ENDOBRONCHIAL AND ENDOSCOPIC ULTRASONOGRAPHY WITH OR WITHOUT ADDITIONAL SURGICAL MEDIASTINOSCOPY (MEDIASTrial)lung cancernon-small cell lung cancerNL-OMON52981Maxima Medisch Centrum356
已完成
4 期
Post-Market Clinical Investigation of the Clareon® IOCataractNL-OMON46484Alcon Laboratories16
已完成
不适用
Multicenter randomized clinical trial in Patients with Juvenile Idiopathic Arthritis and Methotrexate related side effects: Psychological Behavioural therapy versus switch to MTX parenteral versus standard of careJuvenile Idiopathic ArthritisNL-OMON38373niversitair Medisch Centrum Utrecht450